---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Care management intervention strategies"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Care management intervention strategies. Topics: Multidisciplinary care model across primary care, endocrinology, and hepatology (AASLD 2023); Multidisciplinary management recommendation (EASL-EASD-EASO); AGA clinical care pathway: risk stratification in primary care and hepatologist-coordinated care for high-risk patients; ADA Standards of Care 2026: screening and referral of adults with type 2 diabetes or prediabetes; 5 further topics. 9 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/care-management-intervention-strategies"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Care management intervention strategies

<a id="heading-2.2.2.4"></a>

## 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

### Multidisciplinary care model across primary care, endocrinology, and hepatology (AASLD 2023)

> “Optimal care of the patient with NAFLD requires a multidisciplinary approach. The majority of patients are in the primary care/endocrine setting, in which management of medical comorbidities should be optimized, with preference given to treatments for type 2 diabetes mellitus, hypertension, or obesity that likely also have beneficial effects on NAFLD.”
> “The role of the gastroenterologist/hepatologist includes more comprehensive liver risk stratification, exclusion of other liver diseases, and a focus on liver-directed therapy.”
> “All patients should undergo dietary/nutritional assessment and a plan established for regular follow-up independent of gastroenterology/hepatology visits.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.2.4-2"></a>

### Multidisciplinary management recommendation (EASL-EASD-EASO)

> “Given the multidirectional connections between MASLD and cardiometabolic comorbidities, a multidisciplinary approach is recommended to ensure all components are appropriately targeted to improve both liver-related and extrahepatic outcomes (LoE 3, strong recommendation, strong consensus).”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.4-3"></a>

### AGA clinical care pathway: risk stratification in primary care and hepatologist-coordinated care for high-risk patients

> “As a result, FIB-4 provides a useful, inexpensive, first-line assessment of liver fibrosis for use in primary care.”
> “We recommend that these patients be managed by a multidisciplinary team closely coordinated by a hepatologist who can monitor for cirrhosis, HCC, and other cirrhosis-related complications. In these patients, we recommend aggressive lifestyle changes aimed at long-term weight loss.”

Source: [Kanwal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8819923/)

<a id="topic-2.2.2.4-4"></a>

### ADA Standards of Care 2026: screening and referral of adults with type 2 diabetes or prediabetes

> “Adults with type 2 diabetes or prediabetes with a FIB-4 ≥ 1.3 should have additional risk stratification by liver stiffness measurement with transient elastography, or, if unavailable, the enhanced liver fibrosis (ELF) test.”
> “Refer adults with type 2 diabetes or prediabetes at higher risk for significant liver fibrosis (i.e., as indicated by FIB-4, liver stiffness measurement, or ELF) to a gastroenterologist or hepatologist for further evaluation and management.”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.2.4-5"></a>

### On-treatment monitoring and discontinuation criteria for resmetirom at 12 months (AASLD October 2024 update)

> “Hepatic function panel testing should be obtained at baseline and at periodic intervals (eg, 3, 6, and 12 months) to determine response and adverse events while on resmetirom therapy.”
> “In persons whose treatment candidacy was determined by liver stiffness measurements (VCTE or MRE), a repeat measurement at 12 months of therapy is recommended to assess for treatment response.”
> “Among persons with evidence of worsening liver disease at 12 months of treatment, discontinuation of resmetirom should be considered.”

Source: [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated)

<a id="topic-2.2.2.4-6"></a>

### Response and futility assessment for semaglutide at 72 weeks (AASLD November 2025 update)

> “Based on a collective assessment of available data, a reduction from baseline to 72 weeks of VCTE LSM ≥30%, MRE LSM ≥20%, ALT ≥17 U/L or ≥20%, likely reflects a beneficial response. Response below these thresholds but without evidence of worsening or progression to cirrhosis requires individual patient evaluation (Figure 2).”
> “In the absence of data, we recommend consideration of previously recommended criteria,”

Source: [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated)

<a id="topic-2.2.2.4-7"></a>

### Treatment response definition at 1 year (updated global consensus 2026)

> “The panel endorsed a sequential risk-stratification strategy beginning with Fibrosis-4 Index (FIB-4) as the first-line assessment, followed by vibration-controlled transient elastography or Enhanced Liver Fibrosis (ELF) testing for secondary stratification.”
> “Treatment response at 1 year was defined as a ≥30% reduction in liver stiffness or a ≥0.5-point reduction in ELF.”

Source: [Younossi et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/41950980/)

<a id="topic-2.2.2.4-8"></a>

### Pharmacist-led prescription pathway for resmetirom in a US health system

> “Our health system allocated a senior and experienced PharmD pharmacist (Phoebe Shackelford) to champion the resmetirom prescription pathway.”
> “Our prescription pathway effectively dispensed resmetirom to nearly all patients who were prescribed resmetirom.”
> “One in 6 patients discontinued resmetirom, primarily due to side effects. This high discontinuation rate may be mitigated by modifying our follow-up from”

Source: [Ravela et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11970881/)

<a id="topic-2.2.2.4-9"></a>

### Utilization management: national formulary prior authorization criteria for resmetirom and semaglutide in MASH

> “Approve for 1 year if the patient meets ONE of the following (A or B):”
> “Liver biopsy performed within the 3 years preceding treatment with Rezdiffra, Wegovy injection, Wegovy HD injection, or Wegovy tablet [documentation required]; OR”
> “Vibration-controlled transient elastography (VCTE) performed within the 6 months preceding treatment with Rezdiffra, Wegovy injection, Wegovy HD injection, or Wegovy tablet [documentation required]; OR”
> “Patient has completed ≥ 1 year of therapy with Rezdiffra AND according to the prescriber, the patient has not had worsening of fibrosis or MASH/NASH; AND”

Source: [Cigna Rezdiffra prior authorization policy (2026)](https://a.static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_852_coveragepositioncriteria_hepatology_rezdiffra_pa.pdf)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
